Skip to main content

Rindopepimut: anti-EGFRvIII peptide vaccine, oncolytic.

Publication ,  Journal Article
Gedeon, PC; Choi, BD; Sampson, JH; Bigner, DD
Published in: Drugs Future
March 2013

Glioblastoma, the most common primary malignant brain tumor, is among the most difficult cancers to treat. Despite the aggressive standard of care, including surgical removal followed by radiotherapy with concomitant and adjuvant chemotherapy, the often sudden onset, diffuse infiltrating nature and highly malignant features of the lesion result in a median overall survival of < 15 months. Currently employed standard- of-care therapy for glioblastoma is nonspecific, leading to premature withdrawal of treatment due to off-target toxicity. Rindopepimut is a peptide-based vaccine that elicits a potent humoral and cellular immune response specifically against cells expressing EGFRvIII, a rearranged, cell-surface tyrosine kinase receptor present exclusively in glioblastoma and other common neoplasms. Several phase I and phase II clinical trials have demonstrated that vaccination with rindopepimut is safe, well tolerated and produces a highly potent immune response that effectively eradicates EGFRvIII-expressing tumor cells, leading to a 73% increase in survival among patients with newly diagnosed glioblastoma. Furthermore, temozolomide-induced lymphopenia enhances the rindopepimut-induced immune response against EGFRvIII, allowing for enhanced vaccination responses in the context of standard-of-care chemotherapy. Rindopepimut is currently undergoing evaluation in a phase III international trial for newly diagnosed glioblastoma and is under clinical investigation for recurrent glioblastoma and pediatric brain stem gliomas.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Drugs Future

DOI

ISSN

0377-8282

Publication Date

March 2013

Volume

38

Issue

3

Start / End Page

147 / 155

Location

United States

Related Subject Headings

  • Medicinal & Biomolecular Chemistry
  • 3214 Pharmacology and pharmaceutical sciences
  • 1115 Pharmacology and Pharmaceutical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gedeon, P. C., Choi, B. D., Sampson, J. H., & Bigner, D. D. (2013). Rindopepimut: anti-EGFRvIII peptide vaccine, oncolytic. Drugs Future, 38(3), 147–155. https://doi.org/10.1358/dof.2013.038.03.1933992
Gedeon, Patrick C., Bryan D. Choi, John H. Sampson, and Darell D. Bigner. “Rindopepimut: anti-EGFRvIII peptide vaccine, oncolytic.Drugs Future 38, no. 3 (March 2013): 147–55. https://doi.org/10.1358/dof.2013.038.03.1933992.
Gedeon PC, Choi BD, Sampson JH, Bigner DD. Rindopepimut: anti-EGFRvIII peptide vaccine, oncolytic. Drugs Future. 2013 Mar;38(3):147–55.
Gedeon, Patrick C., et al. “Rindopepimut: anti-EGFRvIII peptide vaccine, oncolytic.Drugs Future, vol. 38, no. 3, Mar. 2013, pp. 147–55. Pubmed, doi:10.1358/dof.2013.038.03.1933992.
Gedeon PC, Choi BD, Sampson JH, Bigner DD. Rindopepimut: anti-EGFRvIII peptide vaccine, oncolytic. Drugs Future. 2013 Mar;38(3):147–155.

Published In

Drugs Future

DOI

ISSN

0377-8282

Publication Date

March 2013

Volume

38

Issue

3

Start / End Page

147 / 155

Location

United States

Related Subject Headings

  • Medicinal & Biomolecular Chemistry
  • 3214 Pharmacology and pharmaceutical sciences
  • 1115 Pharmacology and Pharmaceutical Sciences